Emily Patricia Sansone, MSOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4232 Shelby Basin Rd, Medina, NY 14103 Phone: 716-807-3576 |
Wendy Lamirand, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1 Mustang Dr, Medina, NY 14103 Phone: 585-798-2350 |
Lillian Cultrara, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4232 Shelby Basin Rd, Medina, NY 14103 Phone: 716-731-6800 |
Haylee Ewert Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 Ohio St, Medina, NY 14103 Phone: 585-589-2000 |
Carrie Ann Wilson, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5077 Creek Rd, Medina, NY 14103 Phone: 585-798-1476 |
News Archive
Kraton Performance Polymers, Inc., a leading global producer of styrenic block copolymers and other engineered polymers, announces plans to showcase Cariflex polyisoprene products, the pure and clean alternative to natural rubber for high performance medical applications, at MEDTEC Europe in Stuttgart, Germany.
The average incidence of traumatic brain injury (TBI) among service members deployed in Middle East conflict zones has increased 117% in recent years, mainly due to proximity to explosive blasts. Therapeutic exposure to a high oxygen environment was hoped to minimize the concussion symptoms resulting from mild TBI, but hyperbaric oxygen (HBO2) treatment may not offer significant advantages, according to an article in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.
Synta Pharmaceuticals Corp. announced today that the first patients have been treated in the randomized GALAXY-2 Phase 3 trial designed to evaluate docetaxel plus ganetespib, its investigational Hsp90 inhibitor, versus docetaxel alone for the second-line treatment of non-small cell lung adenocarcinoma.
USA Today reports prices may be higher than expected for some middle-class consumers who are not eligible for the health law's subsidies. Meanwhile, Politico highlights how one group - older Capitol Hill staffers - is reacting to this marketplace experience.
› Verified 8 days ago